Biologic Therapy for HLA-B27-associated Ocular Disorders

Julie Gueudry, Jennifer Thorne, Rakesh Bansie, Juergen Braun, P. Martin van Hagen, Bahram Bodaghi

Research output: Contribution to journalArticle

Abstract

The treatment of articular and extra-articular manifestations associated with HLA-B27 has undergone dramatic changes over the past two decades, mainly as a consequence of the introduction of biologic agents and in particular anti-tumor necrosis factor α (anti-TNFα) agents. Uveitis is known to be the most frequent extra-articular feature in HLA-B27-associated spondyloarthritides. Topical corticosteroids and cycloplegic agents remain the cornerstones of treatment. However, biologic therapy may be effective in the management of refractory or recurrent forms of uveitis. This review gives an update on the management of HLA-B27-associated ocular disorders with biologics, including anti-TNFα agents and non-anti-TNFα biologic modifier drugs. There is an emerging role for newer biologics targeting interleukin-12/23 and interleukin-17 for the treatment of spondyloarthritides but data on their efficacy on anterior uveitis are sparse.

Original languageEnglish (US)
Pages (from-to)1-10
Number of pages10
JournalOcular Immunology and Inflammation
DOIs
StateAccepted/In press - Oct 16 2016

Fingerprint

HLA-B27 Antigen
Biological Therapy
Tumor Necrosis Factor-alpha
Joints
Uveitis
Biological Products
Mydriatics
Interleukin-23
Anterior Uveitis
Interleukin-17
Biological Factors
Interleukin-12
Adrenal Cortex Hormones
Therapeutics
Pharmaceutical Preparations

Keywords

  • Anti-TNFα
  • biologics
  • HLA-B27
  • spondyloarthritis
  • uveitis

ASJC Scopus subject areas

  • Immunology and Allergy
  • Ophthalmology

Cite this

Gueudry, J., Thorne, J., Bansie, R., Braun, J., van Hagen, P. M., & Bodaghi, B. (Accepted/In press). Biologic Therapy for HLA-B27-associated Ocular Disorders. Ocular Immunology and Inflammation, 1-10. https://doi.org/10.1080/09273948.2016.1234625

Biologic Therapy for HLA-B27-associated Ocular Disorders. / Gueudry, Julie; Thorne, Jennifer; Bansie, Rakesh; Braun, Juergen; van Hagen, P. Martin; Bodaghi, Bahram.

In: Ocular Immunology and Inflammation, 16.10.2016, p. 1-10.

Research output: Contribution to journalArticle

Gueudry, Julie ; Thorne, Jennifer ; Bansie, Rakesh ; Braun, Juergen ; van Hagen, P. Martin ; Bodaghi, Bahram. / Biologic Therapy for HLA-B27-associated Ocular Disorders. In: Ocular Immunology and Inflammation. 2016 ; pp. 1-10.
@article{3eb2a3584036469aa9f6a07128ac1459,
title = "Biologic Therapy for HLA-B27-associated Ocular Disorders",
abstract = "The treatment of articular and extra-articular manifestations associated with HLA-B27 has undergone dramatic changes over the past two decades, mainly as a consequence of the introduction of biologic agents and in particular anti-tumor necrosis factor α (anti-TNFα) agents. Uveitis is known to be the most frequent extra-articular feature in HLA-B27-associated spondyloarthritides. Topical corticosteroids and cycloplegic agents remain the cornerstones of treatment. However, biologic therapy may be effective in the management of refractory or recurrent forms of uveitis. This review gives an update on the management of HLA-B27-associated ocular disorders with biologics, including anti-TNFα agents and non-anti-TNFα biologic modifier drugs. There is an emerging role for newer biologics targeting interleukin-12/23 and interleukin-17 for the treatment of spondyloarthritides but data on their efficacy on anterior uveitis are sparse.",
keywords = "Anti-TNFα, biologics, HLA-B27, spondyloarthritis, uveitis",
author = "Julie Gueudry and Jennifer Thorne and Rakesh Bansie and Juergen Braun and {van Hagen}, {P. Martin} and Bahram Bodaghi",
year = "2016",
month = "10",
day = "16",
doi = "10.1080/09273948.2016.1234625",
language = "English (US)",
pages = "1--10",
journal = "Ocular Immunology and Inflammation",
issn = "0927-3948",
publisher = "Informa Healthcare",

}

TY - JOUR

T1 - Biologic Therapy for HLA-B27-associated Ocular Disorders

AU - Gueudry, Julie

AU - Thorne, Jennifer

AU - Bansie, Rakesh

AU - Braun, Juergen

AU - van Hagen, P. Martin

AU - Bodaghi, Bahram

PY - 2016/10/16

Y1 - 2016/10/16

N2 - The treatment of articular and extra-articular manifestations associated with HLA-B27 has undergone dramatic changes over the past two decades, mainly as a consequence of the introduction of biologic agents and in particular anti-tumor necrosis factor α (anti-TNFα) agents. Uveitis is known to be the most frequent extra-articular feature in HLA-B27-associated spondyloarthritides. Topical corticosteroids and cycloplegic agents remain the cornerstones of treatment. However, biologic therapy may be effective in the management of refractory or recurrent forms of uveitis. This review gives an update on the management of HLA-B27-associated ocular disorders with biologics, including anti-TNFα agents and non-anti-TNFα biologic modifier drugs. There is an emerging role for newer biologics targeting interleukin-12/23 and interleukin-17 for the treatment of spondyloarthritides but data on their efficacy on anterior uveitis are sparse.

AB - The treatment of articular and extra-articular manifestations associated with HLA-B27 has undergone dramatic changes over the past two decades, mainly as a consequence of the introduction of biologic agents and in particular anti-tumor necrosis factor α (anti-TNFα) agents. Uveitis is known to be the most frequent extra-articular feature in HLA-B27-associated spondyloarthritides. Topical corticosteroids and cycloplegic agents remain the cornerstones of treatment. However, biologic therapy may be effective in the management of refractory or recurrent forms of uveitis. This review gives an update on the management of HLA-B27-associated ocular disorders with biologics, including anti-TNFα agents and non-anti-TNFα biologic modifier drugs. There is an emerging role for newer biologics targeting interleukin-12/23 and interleukin-17 for the treatment of spondyloarthritides but data on their efficacy on anterior uveitis are sparse.

KW - Anti-TNFα

KW - biologics

KW - HLA-B27

KW - spondyloarthritis

KW - uveitis

UR - http://www.scopus.com/inward/record.url?scp=84991463566&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84991463566&partnerID=8YFLogxK

U2 - 10.1080/09273948.2016.1234625

DO - 10.1080/09273948.2016.1234625

M3 - Article

C2 - 27749140

AN - SCOPUS:84991463566

SP - 1

EP - 10

JO - Ocular Immunology and Inflammation

JF - Ocular Immunology and Inflammation

SN - 0927-3948

ER -